Pfizer presented more detailed efficacy data supporting monthly dosing for berobenatide, its acquired obesity GLP-1 receptor agonist from Metsera. In the VESPER-3 mid-stage study, patients transitioned from weekly dosing to monthly injections, and weight loss continued at a similar pace through 28 weeks without an apparent plateau. The company disclosed that patients lost up to 12.1% of weight by week 28 among those who stayed on treatment. Pfizer also noted the competitive question as the market compares monthly regimens against weekly injectables aimed at deeper or faster weight loss.